Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Citations Over Time
Abstract
Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms. While multicentric Castleman disease (UCD) poses a potential therapeutic challenge, unicentric variant has historically been considered curable with surgical resection. Hence, little is known to guide management of patients with UCD, refractory to surgical resection and combination chemotherapy. We present a case of a patient, negative for HIV and HHV-8, who had an unsuccessful surgical intervention and no response to radiotherapy and chemotherapy. He had severe paraneoplastic pemphigus and was treated with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody that has demonstrated good response rates in multicentric Castleman disease but demonstrated no clinical response despite 2 months of treatment. Our report is the first to describe a lack of response to tocilizumab in the rare setting of refractory UCD and discuss potential for distinct disease biology.
Related Papers
- → Post‐transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease(1992)137 cited
- → Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases(2008)11 cited
- → Lymphoproliferative disorders of the orbit: an immunological approach to diagnosis and pathogenesis.(1983)29 cited
- → Absence of Gallium Uptake in Unicentric and Multicentric Castleman's Disease(2003)10 cited
- → Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report(2018)